Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price ...

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus (NASDAQ:MRUS – Free Report) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,467 shares of ...

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Merus (MRUS – Research Report). The associated price target ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

GET MORE AI-GENERATED SIGNALS: October 23, 2024, 07:32 am ET, BY Randall S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short MRUS slightly under 59.06, target 51.8, stop loss @ ...

Idaho – which finished 11-21, with a 5-13 mark in the Big Sky – won half of its preseason games before coming up with some ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...

Team Rebounds: 6. Team Turnovers: None. Blocked Shots: 4 (Crujeiras, Martin, Potter, Whalen). Turnovers: 19 (Whalen 4, Aubry-Thomas 3, Hagan 3, Mugosa 2, Potter 2, Williams 2, Hansen, Martin, Zapater) ...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could ...